Results 31 to 40 of about 14,491 (226)
Thoracic Cancer, 2022 Background There is limited data on the clinical outcome, long‐term survival and tolerability of sequential therapy of first‐line crizotinib followed by alectinib in a real‐world setting for Chinese patients with advanced ALK+ NSCLC.
Zihua Zou +13 more
doaj +1 more source
Control of brain metastases with alectinib in anaplastic lymphoma kinase-rearranged lung cancer [PDF]
, 2017 published_or_final_versio
Ho, JCM +4 more
core +1 more source
Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC
Case Reports in Oncology, 2021 Alectinib is the first-line targeted treatment for advanced ALK-positive non-small-cell lung cancer. Although it has a relatively mild toxicity profile, adverse events (AEs) do occur. We present a case of alectinib-induced bilateral pleural effusions and
Maiken Parm Ulhoi +2 more
doaj +1 more source
Mechanisms of tumor cell resistance to the current targeted-therapy agents [PDF]
, 2016 Resistance to chemotherapy agents is a major challenge infront of cancer patient treatment and researchers. It is known that several factors, such as multidrug resistance proteins and ATP-binding cassette families, are cell membrane transporters that
Hojjat Farsangi, Mohammad +4 more
core +2 more sources
Frontiers in Pharmacology, 2023 Alectinib has been approved as first-line treatment for anaplastic lymphoma kinase (ALK)-positive non-small cell lung carcinoma. Oncologists are also exploring the possibility of applying alectinib in the perioperative period.
Peijun Cao +11 more
doaj +1 more source
Revisiting a lower starting dose of alectinib in ALK-Positive non-small cell lung cancer
Cancer Treatment and Research Communications, 2021 We present here a case of ALK-positive lung adenocarcinoma that has been started on Alectinib. Treatment has been initiated at the recommended initial dose, but it subsequently required a dose adjustment following adverse drug events.
Danielle Benedict Sacdalan +1 more
doaj +1 more source
First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors [PDF]
, 2016 Background ASP3026 is a second-generation anaplastic lymphoma kinase (ALK) inhibitor that has potent in vitro activity against crizotinib-resistant ALK-positive tumors.
Anthony Tolcher +8 more
core +3 more sources
Journal of Medical Case Reports, 2018 Background Lung cancer is among the top causes of cancer-related mortality in men and is the second most common cancer after breast cancer in women. There are approximately 234,030 new cases of lung cancer and 154,050 deaths from lung cancer in 2018 as ...
P Ramachandran +5 more
doaj +1 more source
High-throughput screening of rare metabolically active tumor cells in pleural effusion and peripheral blood of lung cancer patients [PDF]
, 2017 Malignant pleural effusion (MPE), the presence of malignant cells in pleural fluid, is often the first sign of many cancers and occurs in patients with metastatic malignancies.
Deng, Yuliang +9 more
core +2 more sources
Case Reports in Oncology, 2016 Background: Alectinib is an oral drug developed for the treatment of patients with fusion gene encoding echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK)-rearranged non-small cell lung cancer (NSCLC). Here, we present
Tatsuo Kimura +7 more
doaj +1 more source